Sign In
Buy IEX
IDEX Earnings Calls
| Release date | Apr 29, 2026 |
| EPS estimate | $1.78 |
| EPS actual | $2.00 |
| EPS Surprise | 12.36% |
| Revenue estimate | 845.575M |
| Revenue actual | 886.9M |
| Revenue Surprise | 4.89% |
| Release date | Feb 04, 2026 |
| EPS estimate | $2.04 |
| EPS actual | $2.10 |
| EPS Surprise | 2.94% |
| Revenue estimate | 882.271M |
| Revenue actual | 899.1M |
| Revenue Surprise | 1.91% |
| Release date | Oct 29, 2025 |
| EPS estimate | $1.93 |
| EPS actual | $2.03 |
| EPS Surprise | 5.18% |
| Revenue estimate | 861.436M |
| Revenue actual | 878.7M |
| Revenue Surprise | 2.00% |
| Release date | Jul 30, 2025 |
| EPS estimate | $2.00 |
| EPS actual | $2.07 |
| EPS Surprise | 3.50% |
| Revenue estimate | 871.979M |
| Revenue actual | 865.4M |
| Revenue Surprise | -0.754% |
Last 4 Quarters for IDEX
Below you can see how IEX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 30, 2025 |
| Price on release | $164.28 |
| EPS estimate | $2.00 |
| EPS actual | $2.07 |
| EPS surprise | 3.50% |
| Date | Price |
|---|---|
| Jul 24, 2025 | $183.66 |
| Jul 25, 2025 | $185.69 |
| Jul 28, 2025 | $184.43 |
| Jul 29, 2025 | $185.18 |
| Jul 30, 2025 | $164.28 |
| Jul 31, 2025 | $163.51 |
| Aug 01, 2025 | $159.12 |
| Aug 04, 2025 | $158.25 |
| Aug 05, 2025 | $161.84 |
| 4 days before | -10.55% |
| 4 days after | -1.49% |
| On release day | -0.469% |
| Change in period | -11.88% |
| Release date | Oct 29, 2025 |
| Price on release | $173.40 |
| EPS estimate | $1.93 |
| EPS actual | $2.03 |
| EPS surprise | 5.18% |
| Date | Price |
|---|---|
| Oct 23, 2025 | $168.37 |
| Oct 24, 2025 | $167.95 |
| Oct 27, 2025 | $167.60 |
| Oct 28, 2025 | $166.95 |
| Oct 29, 2025 | $173.40 |
| Oct 30, 2025 | $170.30 |
| Oct 31, 2025 | $171.46 |
| Nov 03, 2025 | $168.25 |
| Nov 04, 2025 | $167.86 |
| 4 days before | 2.99% |
| 4 days after | -3.19% |
| On release day | -1.79% |
| Change in period | -0.303% |
| Release date | Feb 04, 2026 |
| Price on release | $212.25 |
| EPS estimate | $2.04 |
| EPS actual | $2.10 |
| EPS surprise | 2.94% |
| Date | Price |
|---|---|
| Jan 29, 2026 | $199.72 |
| Jan 30, 2026 | $198.55 |
| Feb 02, 2026 | $198.22 |
| Feb 03, 2026 | $201.61 |
| Feb 04, 2026 | $212.25 |
| Feb 05, 2026 | $212.94 |
| Feb 06, 2026 | $211.37 |
| Feb 09, 2026 | $210.75 |
| Feb 10, 2026 | $214.58 |
| 4 days before | 6.27% |
| 4 days after | 1.10% |
| On release day | 0.325% |
| Change in period | 7.44% |
| Release date | Apr 29, 2026 |
| Price on release | $217.34 |
| EPS estimate | $1.78 |
| EPS actual | $2.00 |
| EPS surprise | 12.36% |
| Date | Price |
|---|---|
| Apr 23, 2026 | $206.64 |
| Apr 24, 2026 | $204.80 |
| Apr 27, 2026 | $207.39 |
| Apr 28, 2026 | $205.36 |
| Apr 29, 2026 | $217.34 |
| Apr 30, 2026 | $217.85 |
| May 01, 2026 | $214.93 |
| May 04, 2026 | $214.33 |
| May 05, 2026 | $215.76 |
| 4 days before | 5.18% |
| 4 days after | -0.727% |
| On release day | 0.235% |
| Change in period | 4.41% |
IDEX Earnings Call Transcript Summary of Q1 2026
IDEX reported a strong start to FY2026 with Q1 organic revenue up 5%, orders up ~10% organically, and adjusted EBITDA margin expanding 50 basis points to 26%. Strength was concentrated in the Health & Science Technologies (HST) segment (11% sales growth, 17% order growth) driven by data center, semiconductor, space & defense and pharma exposures, resulting in meaningful backlog build and improved visibility. Fluid & Metering Technologies (FMT) saw 9% order growth and 2% organic sales growth (water and pumps performing well), while Fire, Safety & Defense Products (FSDP) was slightly down on orders and sales but showed margin improvement. Management raised full‑year organic growth guidance to 3%–4% (from 1%–2%) and increased adjusted EPS guidance by $0.20 to $8.35–$8.55, while keeping adjusted EBITDA margin guidance at 26.5%–27.0%. First quarter free cash flow was $86M (seasonally low); gross leverage ~2x and liquidity ~$1.1B. Capital allocation remains balanced: $76M of share repurchases in Q1 with that cadence expected through 2026, continued dividends, and active pursuit of bolt‑on M&A. Tariff changes are not expected to have a material net impact; management notes typical risks and geopolitical uncertainty that temper visibility for some short‑cycle industrial end markets.
